Opinion

Video

Expert Perspectives on Venetoclax-Based 1L Treatment Strategies in CLL

Author(s):

Catherine C. Coombs, MD,Bita Fakhri, MD, MPH

Focusing on the CLL13 and CLL14 studies, Bita Fakhri, MD, MPH, provides insights on the role of venetoclax-based first-line combination strategies and factors that inform treatment selection.

Video content above is prompted by the following questions:

  • Discuss the role of venetoclax-based first-line (1L) combination treatment strategies.
    • How do you select patients for venetoclax + rituximab vs venetoclax + obinutuzumab vs venetoclax + ibrutinib?
Related Videos
3 experts are featured in this series.
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
John M. Burke, MD
Related Content
Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL
December 19th 2024

Venetoclax-Based Therapy Is Associated With Worse Outcomes in BTK Inhibitor–Resistant, Chemo-Naive CLL

Misako Nagasaka, MD, PhD, associate professor, Division of Hematology and Oncology, Division of Medicine, University of California Irvine School of Medicine
December 10th 2024

T-DXd Steadily Transforms the NSCLC Treatment Paradigm: With Misako Nagasaka, MD, PhD

Chronic Lymphocytic Leukemia | stock.adobe.com
December 10th 2024

Pirtobrutinib Improves PFS in Previously Treated CLL/SLL

Matthew Lunning, DO, FACP, associate professor, Division of Oncology & Hematology, associate vice chair, research, Department of Internal Medicine, assistant vice chancellor, clinical research, University of Nebraska Medical Center; Sarah Rutherford, MD, assistant professor, medicine, Division of Hematology/Oncology, Weill Cornell Medicine
April 18th 2024

Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin Lymphoma

Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL
December 10th 2024

Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL

B-Cell Malignancies
December 9th 2024

Second-Generation BTK Inhibitors Exhibit Lower Incidence of Cardiac AEs in B-Cell Malignancies